Financing early stage biotech

Like Comment

I read Bruce Booth’s blog, Life Sci VC, when I get the chance, and he’s often lent his skills to Nature Biotechnology. We had him into our offices as part of our Meet the Author series, for example, where he discussed his article on biotech IPOs.

We’ve been cross-posting relevant material from his blog on Trade Secrets, rebuilding the posts from scratch. The truth is, they never look quite as good rebuilt as the do in the original, so I’m providing the link this time. He’s written an interesting piece on funding for early stage biotech. Read it here.

Brady Huggett

Bruce Booth

Chairman, DPhil, Partner

Focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. Currently chairman of AvroBio, miRagen Therapeutics, Nimbus Therapeutics, Rodin Therapeutics, and Quartet Medicine, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapeutics, Unum Therapeutics, and Zafgen (NASDAQ:ZFGN)